Not yet reviewed — this article is pending editorial review by Lyrea.

Eutylone

β-keto-1,3-benzodioxolyl-N-ethylbutanamine

bk-EBDB, N-ethylbutylone, euty

Psychoactive Class

Stimulant Entactogen

Chemical Class

Cathinone (substituted)Phenethylamine (substituted)

Eutylone is a synthetic psychoactive substance of the substituted cathinone and substituted phenethylamine chemical classes.¹² It is classified as both a stimulant and an entactogen, producing a combination of effects that include increased energy and wakefulness alongside enhanced empathy and sociability.² As a synthetic cathinone, eutylone belongs to a broader family of novel psychoactive substances commonly encountered in research chemical markets.¹³

Dosage & Duration

Dosage

Threshold~50 mg

Light50-100 mg

Moderate100-150 mg

Strong150-200 mg

Heavy200+ mg

Duration

Onset15-45 minutes

Peak1-2 hours

After Effects2-6 hours

Total3-5 hours

Subjective Effects

Eutylone produces a primarily stimulating experience with an empathogenic component that is generally described as weaker and less emotionally warm than that of MDMA, for which it has frequently been mis-sold. The effects lean heavily toward physical and mental stimulation, with the entactogenic qualities fading faster than the stimulant ones, leaving a long, wakeful tail. Compulsive redosing is commonly reported as the initial euphoria diminishes.

Physical

Physical effects are dominated by stimulation, including increased heart rate, appetite suppression, and difficulty sleeping that can persist for many hours after the primary effects have subsided.

Stimulation

Increased heart rate

Uncomfortable

Appetite suppression Insomnia

Cognitive

The headspace combines mild euphoria and a muted sense of emotional openness with pronounced mental stimulation. As the experience progresses, the empathogenic warmth tends to give way to a more purely stimulated, sometimes anxious state, and users frequently report a strong urge to redose.

Emotional

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)

Mecke(ME)

Mandelin(MD)

Liebermann(LB)

PROtestkit.eu

Pharmacology

Pharmacodynamics

In rat-brain synaptosome assays, eutylone inhibited uptake at DAT, NET, and SERT. It did not produce efficacious release at DAT or NET, but acted as a partial SERT releasing agent. The investigators therefore characterized eutylone as a hybrid transporter compound: an uptake inhibitor at DAT and NET with substrate-like partial releasing activity at SERT.¹

These preclinical assays do not establish a human therapeutic window, safe dose, or receptor-wide binding profile.¹

Pharmacokinetics

No controlled human clinical pharmacokinetic study is established here. In pooled human liver microsomes and hepatocytes, eutylone showed slow in-vitro turnover: reported half-lives were 972.5 minutes in microsomes and 375.5 minutes in hepatocytes, with a predicted human hepatic extraction ratio of 0.39. These in-vitro values must not be presented as a human elimination half-life.⁴ Cross-species hepatocyte work found pronounced species differences, including much faster rat clearance, so rodent disposition should not be directly extrapolated to humans.⁴

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check

TripSit

Tolerance

Cross Tolerance

Substituted cathinones, Stimulants, Entactogens

Harm Potential

Reported adverse effects include insomnia, anxiety, tachycardia, hypertension, hyperthermia, delirium, paranoia, visual hallucinations, rhabdomyolysis, nausea, vomiting, and seizures. Severe toxicity warrants urgent medical attention.⁵

Addiction & Dependence

Psychological

The WHO review found no animal or human studies of eutylone's dependence potential. It summarized online reports of craving and repeat dosing, but these reports are unconfirmed community evidence and should not be presented as a measured incidence of dependence.⁵

Toxicity

Lethal Dosage

CDC identified 343 eutylone-involved overdose deaths across 44 participating U.S. jurisdictions in 2020. Most involved other drugs: 77.3% also involved illicitly manufactured fentanyls, and 53.1% involved cocaine or methamphetamine. These surveillance data establish serious risk but do not isolate a eutylone-only lethal dose or causal contribution in each polysubstance death.⁶ Long-term human outcomes, a toxic dose threshold, and an exposure-response relationship remain unestablished in the reviewed evidence.⁵

History & Culture

Eutylone was originally developed during the 1960s,¹ though it remained obscure for decades before entering recreational drug markets. The compound was first reported to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 2014, marking its…

Legality

International

Eutylone is internationally controlled in Schedule II of the Convention on Psychotropic Substances of 1971. The Commission on Narcotic Drugs decision entered into force internationally on 23 November 2022.⁸

By Country

United StatesIllegal

DEA's January 2026 Drug & Chemical Evaluation states that eutylone is controlled in Schedule I of the Controlled Substances Act and is not approved for medical use in the United States.²

SwedenIllegal

Eutylone was added through HSLF-FS 2022:48, effective 8 August 2022; the Swedish list records the corresponding international classification as P II.⁹

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Eutylone article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.